OppenheimerFunds Inc. raised its stake in American Renal Associates Holdings Inc (NYSE:ARA) by 44.3% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 403,351 shares of the company’s stock after purchasing an additional 123,773 shares during the period. OppenheimerFunds Inc. owned about 1.24% of American Renal Associates worth $6,361,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other hedge funds also recently bought and sold shares of the company. Engineers Gate Manager LP acquired a new stake in shares of American Renal Associates in the 1st quarter valued at approximately $342,000. Cambridge Investment Research Advisors Inc. acquired a new position in American Renal Associates during the first quarter worth $749,000. Spark Investment Management LLC acquired a new position in American Renal Associates during the first quarter worth $1,010,000. JPMorgan Chase & Co. raised its holdings in shares of American Renal Associates by 34.0% in the first quarter. JPMorgan Chase & Co. now owns 754,951 shares of the company’s stock worth $14,230,000 after acquiring an additional 191,589 shares during the last quarter. Finally, Franklin Resources Inc. raised its holdings in shares of American Renal Associates by 0.9% in the first quarter. Franklin Resources Inc. now owns 756,287 shares of the company’s stock worth $14,256,000 after acquiring an additional 6,478 shares during the last quarter. 93.25% of the stock is currently owned by institutional investors.
Shares of NYSE ARA traded down $0.25 on Friday, hitting $18.96. The company had a trading volume of 129,088 shares, compared to its average volume of 161,045. American Renal Associates Holdings Inc has a 12-month low of $9.91 and a 12-month high of $24.07. The company has a debt-to-equity ratio of 5.30, a current ratio of 1.07 and a quick ratio of 1.04. The company has a market capitalization of $702.91 million, a price-to-earnings ratio of 31.08, a PEG ratio of 3.83 and a beta of 2.51.
A number of equities analysts have recently weighed in on ARA shares. Bank of America cut their price target on American Renal Associates from $25.00 to $21.00 and set a “buy” rating for the company in a report on Tuesday, July 10th. ValuEngine downgraded American Renal Associates from a “hold” rating to a “sell” rating in a research report on Tuesday, July 10th. Zacks Investment Research downgraded American Renal Associates from a “hold” rating to a “sell” rating in a research report on Wednesday, July 11th. Goldman Sachs Group initiated coverage on American Renal Associates in a research report on Thursday, July 19th. They issued a “neutral” rating and a $16.00 price objective for the company. Finally, SunTrust Banks reissued a “buy” rating and set a $25.00 price target on shares of American Renal Associates in a research report on Thursday, August 9th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company. The company has an average rating of “Buy” and an average target price of $22.60.
About American Renal Associates
American Renal Associates Holdings, Inc operates as a dialysis services provider in the United States. It operates dialysis clinics focusing on joint venture partnerships with physicians. The company offers kidney dialysis services to patients suffering from chronic kidney failure or end stage renal disease.
Featured Article: Penny Stocks
Receive News & Ratings for American Renal Associates Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for American Renal Associates and related companies with MarketBeat.com's FREE daily email newsletter.